Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer (Suspended)
Study Number: EA6174 (Suspended)
Study Summary:
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (Suspended)
Status: Suspended
Radiation at UPH-Methodist and Galesburg
Study Coordinator(s)
- Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com
- Amanda , 309-243-3663, amullery@illinoiscancercare.com
